Navigation Links
Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Date:5/24/2012

elop therapies for patients in crisis who are experiencing ischemia (oxygen deprivation of tissues) and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease.

About Sangart
Sangart is a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis. Sangart's therapies are designed to help patients with medical conditions that cause ischemia, such as hemorrhagic shock and sickle cell disease.

To learn more about Sangart, please visit the company's website at www.sangart.com.

Media Contact:
Vivian Cabral
Edelman Public Relations
Office: 323-202-1032
vivian.cabral@edelman.com

 


'/>"/>
SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
2. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
3. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
4. Sangart, Inc. Completes Series F Funding Round
5. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
6. Cerecor Raises $22 Million Series A Financing
7. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
8. Cowen Healthcare Royalty Partners Raises $1 Billion
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... from $107.56 million in 2015, growing at a CAGR of 17.89% between 2015 ... RNA-based aptamers, and XNA-based aptamers. Based on applications, the report is segmented into ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Admin system was developed to solve many of the complex logistical and ... studies that involve multiple clinical sites and/or remote data coordination centers. , ...
(Date:7/6/2015)... ... 2015 , ... A study by a multidisciplinary research team, ... adapt through genetic modifications to fight back against the effects of medication designed ... insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections ...
(Date:7/6/2015)... , July 6, 2015  Emdeon ... into a definitive agreement to acquire Altegra ... intervention platforms that combine data aggregation and ... capabilities to achieve actionable insights and improved ... combine Altegra Health,s risk adjustment and quality ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4
... 16, 2012 Reportlinker.com announces that a new ...   Global ...   This report analyzes ... Million by the following End-Use Segments: Indoor Air ...
... Technologies, Inc. (OTC Bulletin Board: MCET ... Company will present preclinical research findings for MCT-465 ... Europe,s largest meeting dedicated to cancer immunotherapy research ... May 23-25 in Mainz, Germany.  The title of ...
... 15, 2012  OrbusNeich today announced that 12-month follow-up data ... outcomes involving the use of the company,s Combo Dual ... Liberte ® paclitaxel-eluting stent. The data were presented ... the Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012. ...
Cached Biology Technology:Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 2MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 3MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 4MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 5OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 3OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 4
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... Leaders in health care, technology, design, the military and ... Center for the second-annual SINAInnovations conference on November 18 ... A New Era Of Discovery" will highlight the power ... accelerating progress and spurring creativity to advance a culture ...
... been awarded by the Engineering and Physical Sciences Research Council ... to four research projects to study the geological viability and ... and gas fields or saline aquifers. Carbon Capture and ... government meet stringent reductions in CO2 emissions by 2050.1 This ...
... Immune regulation of ovarian development: ... during early life, such as Chlamydia which is ... success in adult women. For example, exposure to bacteria can ... well as in ovarian morphology and sexual behavior. Luba Sominsky ...
Cached Biology News:Mount Sinai celebrates 'team science' at second-annual SINAInnovations Conference Nov. 18-19, 2013 2Research on geological storage of CO2 to reduce greenhouse gas emissions 2Research on geological storage of CO2 to reduce greenhouse gas emissions 3Research on geological storage of CO2 to reduce greenhouse gas emissions 4Research on geological storage of CO2 to reduce greenhouse gas emissions 5Frontiers news briefs: June 6 2Frontiers news briefs: June 6 3
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,523-9) ... assistance. ID clarifier: reusable vial ...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
Biology Products: